UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 1,021 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in BeiGene, Ltd. (NASDAQ:BGNE) by 21.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,786 shares of the company’s stock after selling 1,021 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in BeiGene were worth $850,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of BGNE. Blue Trust Inc. boosted its position in shares of BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after purchasing an additional 75 shares in the last quarter. Raymond James & Associates boosted its holdings in BeiGene by 0.4% in the second quarter. Raymond James & Associates now owns 21,275 shares of the company’s stock worth $3,035,000 after acquiring an additional 76 shares in the last quarter. Truist Financial Corp grew its stake in shares of BeiGene by 10.1% during the second quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock worth $217,000 after acquiring an additional 140 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of BeiGene during the third quarter valued at about $36,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of BeiGene by 0.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company’s stock valued at $21,978,000 after purchasing an additional 266 shares during the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Stock Down 0.7 %

Shares of BGNE opened at $174.72 on Friday. The stock’s 50-day moving average price is $202.18 and its 200-day moving average price is $187.34. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $17.02 billion, a price-to-earnings ratio of -21.20 and a beta of 0.57. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $248.16.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. BeiGene’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. On average, sell-side analysts predict that BeiGene, Ltd. will post -5.64 EPS for the current year.

Wall Street Analyst Weigh In

BGNE has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd. Morgan Stanley reissued an “overweight” rating and issued a $300.00 target price on shares of BeiGene in a research report on Tuesday, December 3rd. TD Cowen lifted their price target on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. StockNews.com lowered BeiGene from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities began coverage on BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.69.

Insider Activity at BeiGene

In other news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $187.27, for a total transaction of $194,202,173.59. Following the completion of the transaction, the director now directly owns 791,493 shares of the company’s stock, valued at $148,222,894.11. This represents a 56.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Xiaodong Wang sold 40,468 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,131,622 shares of company stock worth $212,520,787. 7.43% of the stock is owned by company insiders.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.